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In this review, several glycosaminoglycan analogs obtained from different marine
invertebrate are reported. The structure, biological activity and mechanism of action of
these unique molecules are detailed reviewed and exemplified by experiments in vitro
and in vivo. Among the glycans studied are low-sulfated heparin-like polymers from
ascidians, containing significant anticoagulant activity and no bleeding effect; dermatan
sulfates with significant neurite outgrowth promoting activity and anti-P-selectin from
ascidians, and a unique fucosylated chondroitin sulfate from sea cucumbers, possessing
anticoagulant activity after oral administration and high anti P- and L-selectin activities. The
therapeutic value and safety of these invertebrate glycans have been extensively proved
by several experimental animal models of diseases, including thrombosis, inflammation
and metastasis. These invertebrate glycans can be obtained in high concentrations from
marine organisms that have been used as a food source for decades, and usually
obtained from marine farms in sufficient quantities to be used as starting material for
new therapeutics.
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INTRODUCTION
Heparin is a highly sulfated glycosaminoglycan composed by dis-
accharide units containing a hexuronic acid (α-L-iduronic acid or
β-D-glucuronic acid) linked 1,4 to α-D-glucosamine. The hep-
arin molecules consist of a heterogeneous mixture of polymers
with a similar backbone, which results from variations of sulfation
on the D-glucosamine (N-acethylated, N-sulfated, O-sulfated at
C6 and/or C3) and on the uronic acid residue (O-sulfated at C2)
(Lindahl et al., 1989).
Because of its unique binding to antithrombin, involving
a specific pentasaccharide sequence containing a 3-O-sulfated
glucosamine, heparin is endowed of a potent anticoagulant
activity (Lindahl et al., 1980, 1989). In fact, based on its
ability to inhibit fluid phase coagulation, unfractionated hep-
arin (UF) isolated from porcine and bovine intestinal mucosa
has been used clinically for decades. However, the therapeu-
tic use of UH is limited mostly by its potent hemorrhagic
effect, implying that patients under heparin therapy have to be
Abbreviations: HexA, hexuronic acid; GlcA, glucuronic acid; IdoA, iduronic
acid; GalNAc, N-acetyl galactosamine; GlcNAc, N-acetyl glucosamine; GlcA2S,
2-O-sulfated glucuronic acid; GlcA3S, 3-O-sulfated glucuronic acid; IdoA2S, 2-O-
sulfated iduronic acid; GalNAc4S, 4-O-sulfated N-acetyl galactosamine; GalNAc6S,
6-O-sulfated N-acetyl galactosamine; GalNAc4S,6S, 4-O- and 6-Osulfated N-
acetyl galactosamine; GlcNS, N-sulfated glucosamine; GlcNS,6S, N- and 6-sulfated
glucosamine; GlcNS,3S,6S, N, 3-O- and 6-Osulfated glucosamine.
closely monitored (Hirsh, 1984). UH also has poor bioavailabil-
ity, requires multiple daily dosing, and has side effects such as
heparin-induced thrombocytopenia (Hirsh and Raschke, 2004;
Hirsh et al., 2004). To circumvent these problems, different low-
molecular-weight heparins (LMW-Hep) have been produced by
degrading UF, using a variety of methods, including chemical
depolymerization and enzymatic digestion (Hirsh and Raschke,
2004).
In addition to its anticoagulant effect, mammalian UH has
also anti-inflammatory effect in several animal models of inflam-
mation, which is possibly mediated by P- and L-selectins. The
recruitment of leukocytes from blood and lymphatic systems
into tissues facilitates the response to tissue injury. Adhesion
molecules of the selectin family (E, P, and L) mediate the ini-
tial events that direct the movement of leukocytes across the
endothelium in inflamed tissues by interacting with sialylated,
fucosylated carbohydrate antigens related to sialyl Lewisx [Slex,
Neu5Acα2,3Galβ1,4(Fucα1,3)GlcNAcβ-] found at the cell sur-
face (Lasky, 1995; McEver, 1995; Nelson et al., 1995; Butcher
and Picker, 1996). It has been reported (Stevenson et al., 2005)
that the dose of UH required for the inhibitory effect on the
selectins is higher than that required for the anticoagulant action,
which increases the hemorrhagic risk and makes the clinical use
of UH impractical to treat inflammation. Similarly, the use of
LMW-Hep, which has a much lower hemorrhagic effect, is not
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a good alternative for UH, since it is a poor inhibitor of selectins
(Stevenson et al., 2005).
UF and heparin-like oligosaccharides inhibit L- and P-selectin
binding to Slex and has been shown to dramatically reduce leuko-
cyte infiltration in thioglycollate-induced peritoneal inflamma-
tion inmice (Burg et al., 1997;Wang et al., 2002). In addition, UH
has also been used successfully as a therapeutic agent in different
animal models of nephropathy. Subcutaneous injection of non-
anticoagulant UH reduces glomerulosclerosis in rats (Burg et al.,
1997), and ameliorates the progression of renal disease in rats
with subtotal renal ablation (Purkerson et al., 1988). In addition,
it has also been demonstrated that heparin inhibits macrophage
infiltration and TGF-β synthesis in puromycin glomerulosclerosis
(Ceol et al., 2003).
The risk of contamination with pathogens is an important
aspect to take into account in the therapeutic use of natural
products from mammalian origin. For example, the associa-
tion of mammalian prionic proteins with transmissible spongi-
form encephalopathy has restricted the use of bovine heparin
in Europe, USA and Japan. In these countries, commercial hep-
arin is obtained exclusively from porcine tissues and the risk
of contamination with a prionic protein or even a virus is still
present.
Therefore, as we consider the molecular mechanism of the
anti-inflammatory effect of UF, its side effects, and the possi-
bility of pathogen contamination, it becomes extremely relevant
the search for alternative heparin-like compounds, obtained from
non-mammalian sources, possessing similar biological activities,
but devoid of the undesired side effects.
UNIQUE INVERTEBRATE GLYCOSAMINOGLYCANS
HEPARIN-LIKE GLYCANS
Heparin with a structure similar to that of vertebrate heparin but
with lower anticoagulant activity has been identified in the tissues
of the ascidian Styela plicata (Chordata-Tunicata) (Cavalcante
et al., 2000). An extensive structural analysis of the polymer indi-
cated that the invertebrate heparin is composed mainly of the dis-
accharide α-L-IdoA(2SO4)-1→4β-D-GlcN(SO4)(6SO4)-1, with
a minor contribution (∼25%) of the disaccharide α-L-IdoA-
1→4β-D-GlcN(SO4)(6SO4)-1. Activated partial thromboplastin
time (APTT) assays of the ascidian heparin showed that the poly-
mer has lower anticoagulant activity than mammalian heparin.
In addition, it is about 20 times less potent than mammalian hep-
arin in stimulating the inhibition of thrombin by purified ATIII.
However, S. plicata heparin activates HCII with approximately the
same potency as vertebrate heparin, as indicated by comparison
of the IC50 values for inhibition of thrombin by purified HCII. To
compare the hemorrhagic effect of the ascidian and mammalian
heparin, we used a rat cut-tail bleeding model. S. plicata heparin
at a dose of 4mg/kg body weight, which is above the dose required
to prevent thrombus on an animal experimental model did not
increase the amount of blood loss in comparison with the saline
control. In contrast, mammalian heparin, compared to the con-
trol, increased blood loss almost 2-fold (Cardilo-Reis et al., 2006).
In a TNBS-induced colitis model in rats, S. plicata heparin
drastically reduced inflammation after subcutaneous administra-
tion during a 7-day period (Belmiro et al., 2009), as observed
by the normalization of the macroscopic and histological charac-
teristics of the colon. At molecular level, TNF-alpha, TGF-beta,
and VEGF were reduced to normal values. Lymphocyte and
macrophage recruitment and epithelial cell apoptosis were also
decreased after the treatment. A drastic reduction in collagen-
mediated fibrosis was also observed. No hemorrhagic events were
observed after glycan treatment (Belmiro et al., 2009). These
results strongly indicate a potential therapeutic use of the ascid-
ian heparin in the treatment of colonic inflammation with a lower
risk of hemorrhage, when compared with mammalian heparin.
The bivalve mollusk Nodipecten nodosus, currently cultivated
in different parts of the world with an annual production of
about 75,000 tons (http://www.fao.org/fishery/topic/14884/en),
has been shown to contain high amounts of a heparan sulfate-like
glycosaminoglycan. 1D 1H, 2D COZY and HSQC nuclear mag-
netic resonance revealed characteristic signals of non-sulfated,
3- or 2-sulfated glucuronic acid, as well as N-sulfated and/or 6-
sulfated glucosamine (Gomes et al., 2010). The mollusk glycan
possesses an anticoagulant activity of 36 IU mg−1, 5-fold lower
than bovine heparin (180 IU mg−1). It inhibits factor Xa (IC50 =
0.835μgmL−1) and thrombin (IC50 = 9.3μgmL−1) in the pres-
ence of antithrombin. Experiments in vivo, demonstrated that,
the mollusk HS inhibited thrombus growth in photochemicaly
injured arteries, at the dose of 1mg Kg−1. No bleeding effect, fac-
tor XIIa-mediated kallikrein activity or toxic effect on fibroblast
cells were induced by the invertebrate HS at the antithrombotic
dose (Gomes et al., 2010).
OVERSULFATED DERMATANS
The ascidians S. plicata and Halocyntia pyriformis, con-
tain dermatan sulfates formed by [α-L-IdoA(2SO4)-1→3β-D-
GalNAc(4SO4)] disaccharide units. These oversulfated dermatans
have high heparin cofactor II-mediated anticoagulant activity
(Pavao et al., 1998). Due to a higher concentration of [α-
L-IdoA(2SO4)-1→3β-D-GalNAc(4SO4)]-containing sequences,
that bind to the glycosaminoglycan binding site in the inhibitor,
their heparin cofactor II activities are at least 10 times higher than
that of the mammalian counterpart.
The occurrence of a well-defined relationship between sul-
fate position on the disaccharides and biological activity can
be observed studying dermatan sulfates from different species
of ascidians. In the ascidian Phallusia nigra, the dermatan sul-
fate has the same degree of sulfation of that from S. pli-
cata, but is composed mainly by [α-L-IdoA(2SO4)-1→3β-D-
GalNAc(6SO4)] disaccharide units (Pavao et al., 1995). As a
result of the different sulfation on the N-acetylgalactosamine (6-
sulfated instead of 4-sulfated), P. nigra dermatan sulfate has very
low heparin cofactor II-mediated anticoagulant activity. Overall,
these results strongly suggest that binding of oversulfated der-
matan sulfate polymers to heparin cofactor II requires a specific
sulfation pattern on the glycans, composed by [α-L-IdoA(2SO4)-
1→3β-D-GalNAc(4SO4)]-enriched sequences.
These unique oversulfated dermatan sulfates from ascidians,
with different heparin cofactor II activities, allowed the study
of the relationship between heparin cofactor II activity and
antithrombotic effect. Thus, after intravascular administration
S. plicata dermatan sulfate, with high heparin cofactor II activity,
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prevents thrombus formation in veins (Vicente et al., 2001). On
the other hand, P. nigra dermatan sulfate, with a discernible hep-
arin cofactor II activity, has no antithrombotic effect in the same
venous thrombotic model and dose (Vicente et al., 2001). These
results indicate that a heparin cofactor II-mediated mechanism
is associated with the antithrombotic effect of dermatan sulfate
polymers.
The oversulfated dermatan sulfates from the ascidian P. nigra
and S. plicata, composed by [α-L-IdoA(2SO4)-1→3β-D-GalNAc
(6SO4)] and [α-L-IdoA(2SO4)-1→3β-D-GalNAc(4SO4)] disac-
charide unities were used in the study of mouse hippocampal
neurons behavior. P. nigra dermatan possesses significant neurite
outgrowth-promoting activity, which resulted specific morpho-
logical features. The ascidian dermatan sulfate induced a flat-
tened neuronal cell soma and dendrite-like multiple neurites
(Hikino et al., 2003). S. plicata dermatan sulfate, composed by
[α-L-IdoA(2SO4)-1→3β-D-GalNAc(4SO4)], on the other hand,
exhibited only a modest neurite outgrowth-promoting activity
(Hikino et al., 2003; Bao et al., 2005).
Heparin has been shown to exhibit P- and/or L-selectin-
mediated antimetastatic and antiinflammatory activities.
P-selectin-mediated platelet-tumor cell and tumor-cell endothe-
lium interactions facilitate the initial steps of hematogeneous
metastasis (Borsig et al., 2001, 2002). The dermatan sulfates
from S. plicata and P. nigra, that contain the same disaccha-
ride core structure [α-L-IdoA(2SO4)-1→3β-D-GalNAc]n, but
sulfated at carbon 4 or 6 of the GalNAc residues, respectively,
and opposed HCII activities are potent inhibitors of P-selectin
(Kozlowski and Pavao, 2011; Kozlowski et al., 2011). Both
ascidian dermatan sulfates regardless of the position of sulfation
on the N-acetylgalactosamine drastically attenuate metastasis
of both MC-38 colon carcinoma and B16-BL6 melanoma cells,
and the infiltration of inflammatory cells in a thioglycollate
peritonitis mouse model (Kozlowski and Pavao, 2011; Kozlowski
et al., 2011). Additionally, both ascidians glycosaminoglycans
reduced thrombus size in a FeCl3-induced arterial thrombosis
model, irrespective of their HCII activities. Interestingly, the
arterial thrombi demonstrated a markedly reduced platelet
deposition after dermatan sulfate treatment (Kozlowski and
Pavao, 2011; Kozlowski et al., 2011), suggesting that the ascidians
glycosaminoglycan inhibited P-selectin and thereby the binding
of activated platelets during thrombus formation. These results
provide evidence that inhibition of P-selectin is a potential
therapeutic target in thrombosis, inflammation and metastasis,
and ascidian dermatan sulfates may serve as anti-selectin agents.
FUCOSYLATED CHONDROTITIN SULFATE
A unique natural chondroitin sulfate analog, containing sul-
fated fucose branches has been identified in several species of
sea cucumbers (Vieira and Mourao, 1988; Vieira et al., 1991;
Kariya et al., 1997). The Ludwigothurea grisea glycan has a core
like that of mammalian chondroitin sulfate but substituted at the
3-position of the glucuronic acid residues with fucose-2,4 disul-
fated branches (Vieira and Mourao, 1988; Vieira et al., 1991).
The fucosylated chondroitin sulfate has high anticoagulant and
antithrombotic activities that disappear after removal of the sul-
fated fucose branches by mild acid hydrolysis (Mourao et al.,
1996). Two anticoagulant mechanism have been proposed: activa-
tion of thrombin inhibition by heparin cofactor II, and inhibition
of factor-Xa and thrombin generation by the tenase and pro-
thrombinase complexes, respectively (Glauser et al., 2008; Buyue
and Sheehan, 2009).
Interestingly, thrombosis inhibition in artery by the fuco-
sylated chondroitin sulfate occurs at low doses, and does not
modify the plasma anticoagulant activity. On the contrary, in
venous thrombosis the antithrombotic activity of the fucosylated
chondroitin requires high doses and occurs with an increase in
the plasma anticoagulant activity (Zancan and Mourao, 2004).
Additionally, daily oral doses of this glycosaminoglycan showed
a decrease in thrombus weight on experimental models of venous
and arterial thrombosis in experimental animals (Fonseca and
Mourao, 2006).
The fucosylated chondroitin sulfate from H. grisea inhib-
ited P- and L-selectin binding to immobilized sialyl Lewisx, a
component of leukocyte surface glycoproteins, which is also over-
expressed in several tumor cells (Borsig et al., 2007). The glycan
also inhibited LS180 carcinoma cell attachment to immobilized
P- and L-selectins (Borsig et al., 2007). As a result of its anti-
selectin effect, the intact sea cucumber glycan attenuates lung
colonization by adenocarcinoma MC-38 cells in an experimen-
tal metastasis model in mice, as well as neutrophil recruitment in
thioglycollate-induced peritonitis. Removal of the sulfated fucose
branches abolishes the inhibitory effect in vitro and in vivo (Borsig
et al., 2007). These results suggest that this glycan may be a poten-
tial therapeutic drug for blocking metastasis and inflammatory
reactions.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Glycosaminoglycans analogs with unique structures and phar-
macological activities have been described in different marine
invertebrates (Table 1). The structure, biological activity and
mechanism of action have been extensively studied and the gly-
cans evaluated in pre-clinical experiments in rodent animals with
promising results. Heparin-like polymers with low anticoagulant
activity, significant antithrombotic and anti-inflammatory activ-
ities, but devoid of bleeding effects occur in different species
of ascidians and mollusks. Similarly, oversulfated dermatan sul-
fates containing the same disaccharide core structure of [α-L-
IdoA(2SO4)-1→3β-D-GalNAc]n, but differing in the position of
sulfation (4-sulfate or 6-sulfate) on the N-acetylgalactosamine,
occur in high amounts in ascidians. These polymers have high
anti-selectin activity, which results in attenuation of metasta-
sis and leukocyte recruitment. The 2,6-sulfated dermatan sul-
fate from P. nigra has very low heparin cofactor II activity and
antithrombotic effect, different from its 2,4-sulfated high antico-
agulant counterpart from S. plicata. The anti-P-selectin activity
of these disulfated glycans is involved in low platelet arterial
thrombus formation. Moreover a significant neurite outgrowth
promoting activity is associated with the di-sulfated ascidian der-
matan sulfates. The fucosylated chondroitin sulfate from L.grisea
has significant therapeutic effect after oral administration, atten-
uating metastasis and inflammation due to the high anti-selectin
activity of the sulfated fucose branches. So far, no significant
toxic effect has been associated with the use of these marine
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compounds. Themarine invertebrates that are the primary source
of these potential therapeutic compounds abound in different
parts of the world, mainly in western seas, where they are culti-
vated in large scale. In general, the marine invertebrate glycans
occur in higher concentration in the tissue (about 0.5% of the
dry weight, comparing to 0.022% from pig intestinal mucosa)
and can be easily isolated by procedures similar to those already
employed in the preparation of pharmaceutical heparin. Whereas
these marine organisms will be a source of new heparin analogs
with significant therapeutic effect in thrombosis, inflammation
and cancer in the future will depend on the economic pressure
of the pharmaceutical industry and the increasing demand for
new natural drugs with less undesired side effects to treat specific
diseases.
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